Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis AMERICAN JOURNAL OF HEMATOLOGY O'Brien, S. M., Byrd, J. C., Hillmen, P., Coutre, S., Brown, J. R., Barr, P. M., Barrientos, J. C., Devereux, S., Robak, T., Reddy, N. M., Kipps, T. J., Tedeschi, A., Cynnbalista, F., Ghia, P., Chang, S., Ninomoto, J., James, D. F., Burger, J. A. 2019; 94 (5): 554–62

View details for DOI 10.1002/ajh.25436

View details for Web of Science ID 000468303900006